TEL AVIV, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference.
|Piper Jaffray 27th Annual Healthcare Conference|
|Panel Title:||"Underdiscovered NeuroInnovators"|
|Date:||Wednesday, December 2|
|Location:||Lotte New York Palace, New York, NY|
|Presenter:||Dr. Tomer Berkovitz, CFO|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 firstname.lastname@example.org Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 email@example.com